406 related articles for article (PubMed ID: 26655620)
1. SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT.
Chhablani J; Narayanan R; Mathai A; Yogi R; Stewart M
Retina; 2016 Jun; 36(6):1126-31. PubMed ID: 26655620
[TBL] [Abstract][Full Text] [Related]
2. SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT.
Chhablani J; Dedhia CJ; Peguda HK; Stewart M
Retina; 2017 Oct; 37(10):1859-1865. PubMed ID: 28060148
[TBL] [Abstract][Full Text] [Related]
3. INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results.
de Oliveira Dias JR; Costa de Andrade G; Kniggendorf VF; Novais EA; Takahashi VKL; Maia A; Meyer C; Watanabe SES; Farah ME; Rodrigues EB
Retina; 2019 Apr; 39(4):648-655. PubMed ID: 29232334
[TBL] [Abstract][Full Text] [Related]
4. CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
de Oliveira Dias JR; de Andrade GC; Kniggendorf VF; Novais EA; Maia A; Meyer C; Watanabe SES; Farah ME; Rodrigues EB
Retina; 2017 Aug; 37(8):1499-1507. PubMed ID: 27798520
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration.
de Oliveira Dias JR; Xavier CO; Maia A; de Moraes NS; Meyer C; Farah ME; Rodrigues EB
Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):91-4. PubMed ID: 25559518
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration.
Braimah IZ; Stewart M; Videkar C; Dedhia CJ; Chhablani J;
Br J Ophthalmol; 2017 Sep; 101(9):1201-1205. PubMed ID: 28119292
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes.
Chang AA; Broadhead GK; Hong T; Joachim N; Syed A; Schlub TE; Toth L; Peto T; Zhu M
Ophthalmic Res; 2015; 55(2):84-90. PubMed ID: 26637166
[TBL] [Abstract][Full Text] [Related]
8. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
[TBL] [Abstract][Full Text] [Related]
9. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Loading Doses of Ziv-Aflibercept and Aflibercept in Neovascular Age-Related Macular Degeneration.
Ayachit A; Singh SR; Subramanyam A; Tiwari S; Heranjal A; Chattannavar G; Pandey P; Salti H; Mansour MA; Mansour A; Chhablani J
Asia Pac J Ophthalmol (Phila); 2020; 9(2):144-148. PubMed ID: 32175924
[TBL] [Abstract][Full Text] [Related]
11. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
[TBL] [Abstract][Full Text] [Related]
12. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
[TBL] [Abstract][Full Text] [Related]
13. Ziv-aflibercept in macular disease.
Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
[TBL] [Abstract][Full Text] [Related]
14. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
Braimah IZ; Agarwal K; Mansour A; Chhablani J;
Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
[TBL] [Abstract][Full Text] [Related]
15. OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Identification of Choroidal Neovascularization Activity by Location and Quantification of Abnormal Fluid Under Anti-Vascular Endothelial Growth Factor Therapy.
Farinha C; Santos T; Santos AR; Lopes M; Alves D; Silva R; Cunha-Vaz J
Retina; 2020 May; 40(5):881-890. PubMed ID: 30689620
[TBL] [Abstract][Full Text] [Related]
16. Ziv-aflibercept for Better Regulating Neovascular Age-Related Macular Degeneration (ZEBRA): A Prospective, Randomized Trial.
D'Souza HS; Kapoor KG; Wagner AL
Semin Ophthalmol; 2021 Feb; 36(1-2):28-34. PubMed ID: 33577373
[TBL] [Abstract][Full Text] [Related]
17. Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration.
Mansour AM; Chhablani J; Antonios RS; Yogi R; Younis MH; Dakroub R; Chahine H
Br J Ophthalmol; 2016 Dec; 100(12):1629-1633. PubMed ID: 27030277
[TBL] [Abstract][Full Text] [Related]
18. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of ziv-aflibercept in retinal diseases.
Mansour AM; Ashraf M; Dedhia CJ; Charbaji A; Souka AAR; Chhablani J
Br J Ophthalmol; 2017 Oct; 101(10):1374-1376. PubMed ID: 28270485
[TBL] [Abstract][Full Text] [Related]
20. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
